OA11547A - Quinoline derivatives. - Google Patents

Quinoline derivatives. Download PDF

Info

Publication number
OA11547A
OA11547A OA1200000301A OA1200000301A OA11547A OA 11547 A OA11547 A OA 11547A OA 1200000301 A OA1200000301 A OA 1200000301A OA 1200000301 A OA1200000301 A OA 1200000301A OA 11547 A OA11547 A OA 11547A
Authority
OA
OAPI
Prior art keywords
ethyl
methyl
propyl
daims
quinoline
Prior art date
Application number
OA1200000301A
Other languages
English (en)
Inventor
Anders Bjork
Stig Jonsson
Tomas Fex
Gunnar Hedlund
Original Assignee
Active Biotech Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Active Biotech Ab filed Critical Active Biotech Ab
Publication of OA11547A publication Critical patent/OA11547A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
OA1200000301A 1998-04-27 1999-04-26 Quinoline derivatives. OA11547A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9801474A SE9801474D0 (sv) 1998-04-27 1998-04-27 Quinoline Derivatives

Publications (1)

Publication Number Publication Date
OA11547A true OA11547A (en) 2004-05-24

Family

ID=20411103

Family Applications (1)

Application Number Title Priority Date Filing Date
OA1200000301A OA11547A (en) 1998-04-27 1999-04-26 Quinoline derivatives.

Country Status (33)

Country Link
EP (1) EP1073639B1 (id)
JP (1) JP4045069B2 (id)
KR (1) KR100571534B1 (id)
CN (1) CN1113057C (id)
AP (1) AP1293A (id)
AT (1) ATE228505T1 (id)
AU (1) AU747550B2 (id)
BR (1) BR9909925B1 (id)
CA (1) CA2329788C (id)
CZ (1) CZ297439B6 (id)
DE (1) DE69904162T2 (id)
DK (1) DK1073639T3 (id)
EE (1) EE04275B1 (id)
ES (1) ES2188242T3 (id)
HK (1) HK1036618A1 (id)
HR (1) HRP20000726B1 (id)
HU (1) HU227709B1 (id)
ID (1) ID26277A (id)
IL (2) IL138160A0 (id)
IS (1) IS2082B (id)
ME (1) ME00870B (id)
NO (1) NO315606B1 (id)
NZ (1) NZ506641A (id)
OA (1) OA11547A (id)
PL (1) PL190441B1 (id)
PT (1) PT1073639E (id)
RS (1) RS50029B (id)
RU (1) RU2197481C2 (id)
SE (1) SE9801474D0 (id)
TR (1) TR200003061T2 (id)
UA (1) UA60354C2 (id)
WO (1) WO1999055678A1 (id)
ZA (1) ZA200004601B (id)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0002320D0 (sv) * 1999-10-25 2000-06-21 Active Biotech Ab Malignant tumors
SE0201778D0 (sv) * 2002-06-12 2002-06-12 Active Biotech Ab Process for the manufacture of quinoline derivatives
KR100908655B1 (ko) 2002-11-27 2009-07-21 엘지디스플레이 주식회사 데이터 공급시간의 변조방법과 이를 이용한액정표시장치의 구동방법 및 장치
SE0400235D0 (sv) * 2004-02-06 2004-02-06 Active Biotech Ab New composition containing quinoline compounds
SE0401578D0 (sv) * 2004-06-18 2004-06-18 Active Biotech Ab Novel compounds
US7838522B2 (en) 2004-11-17 2010-11-23 Ares Trading S.A. Benzothiazole formulations and use thereof
US7973039B2 (en) 2004-12-21 2011-07-05 Merck Serono Sa Sulfonyl amino cyclic derivatives and use thereof
JP4950070B2 (ja) 2005-01-31 2012-06-13 メルク セローノ ソシエテ アノニム Ｎ−ヒドロキシアミド誘導体及びその使用
BRPI0613042A2 (pt) 2005-07-15 2010-12-14 Serono Lab inibidores de jnk para o tratamento de endometriose
KR20080044836A (ko) 2005-07-15 2008-05-21 라보라뚜와르 세로노 에스. 에이. 자궁내막증 치료용 ｊｎｋ 억제제
WO2007025991A2 (en) 2005-09-01 2007-03-08 Ares Trading S.A. Treatment of optic neuritis
CN103333107A (zh) * 2005-10-19 2013-10-02 泰华制药工业有限公司 拉奎尼莫钠晶体及其制备方法
BRPI0713694A2 (pt) * 2006-06-12 2012-10-30 Teva Pharma composição farmacêutica, processo para preparar composição farmacêutica, embalagens vedada, métodos para tratar um indivìduo afligido com uma forma de esclerose múltipla, e para aliviar um sintoma de esclerose múltipla em um indivìduo afligido com uma forma de esclerose múltipla, e, uso da composição farmacêutica
EP2682120B1 (en) 2007-12-20 2016-08-03 Teva Pharmaceutical Industries, Ltd. Stable laquinimod preparations
NZ591315A (en) * 2008-09-03 2012-08-31 Teva Pharma 2-oxo-1,2-dihydro-quinoline modulators of immune function
KR20120045032A (ko) * 2009-07-30 2012-05-08 테바 파마슈티컬 인더스트리즈 리미티드 라퀴니모드를 이용한 크론병의 치료
HUE029983T2 (en) 2009-08-10 2017-04-28 Teva Pharma Treatment of BDNF-related diseases with laquinimod
PT2542079E (pt) * 2010-03-03 2014-07-18 Teva Pharma Tratamento da artrite reumatoide com uma combinação de laquinimod e metotrexato
EA201290837A1 (ru) 2010-03-03 2013-05-30 Тева Фармасьютикал Индастриз Лтд. Лечение волчаночного нефрита с применением лаквинимода
WO2011109536A1 (en) * 2010-03-03 2011-09-09 Teva Pharmaceutical Industries Ltd. Treatment of lupus arthritis using laquinimod
WO2011116091A1 (en) 2010-03-17 2011-09-22 Novartis Ag Dispenser
JP5881691B2 (ja) 2010-07-09 2016-03-09 アクティブ バイオテック エイビー キノリン−３−カルボキサミドの製造方法
EP3213636A1 (en) * 2010-07-09 2017-09-06 Teva Pharmaceutical Industries, Ltd. Deuterated n-ethyl-n-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof
MX2013000332A (es) * 2010-07-09 2013-02-26 Teva Pharma 5-cloro-4-hidroxi-1-metil-2-oxo-n-fenil-1,2-dihidroquinolina-3-ca rboxamida, sales y usos de la misma.
EP2444086A1 (en) 2010-10-22 2012-04-25 Almirall, S.A. Combinations comprising DHODH inhibitors and COX inhibitors
KR20140101333A (ko) 2011-10-12 2014-08-19 테바 파마슈티컬 인더스트리즈 리미티드 라퀴니모드 및 핑골리모드의 조합을 이용한 다발성 경화증의 치료
TW201345527A (zh) * 2012-02-03 2013-11-16 Teva Pharma 拉喹莫德於治療對第一線抗－ＴＮＦα療法無效之克隆氏症患者之用途
MX2014009889A (es) 2012-02-16 2014-11-13 Teva Pharma N-etil-n-fenil-1,2-dihidro-4,5-di-hidroxi-1-metil-2-oxo-3-quinoli ncarboxamida, preparacion y usos de los mismos.
TW201350467A (zh) 2012-05-08 2013-12-16 Teva Pharma Ｎ－乙基－４－羥基－１－甲基－５－（甲基（２，３，４，５，６－五羥基己基）胺基）－２－側氧－ｎ－苯基－１，２－二氫喹啉－３－甲醯胺
TW201400117A (zh) * 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
TW201410244A (zh) 2012-08-13 2014-03-16 Teva Pharma 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
US8975279B2 (en) 2012-11-07 2015-03-10 Teva Pharmaceutical Industries, Ltd. Amine salts of laquinimod
RU2545056C2 (ru) * 2012-12-10 2015-03-27 Государственное бюджетное образовательное учреждение высшего профессионального образования "Пермская государственная фармацевтическая академия" Министерства здавоохранения и социального развития Российской Федерации (ГБОУ ВПО ПГФА Минздравсоцразвития России) Противовоспалительное и анальгетическое средство на основе изопропиламида 1,2-дигидро-1н-2-оксоцинхониновой кислоты
MX2015010296A (es) * 2013-02-15 2016-05-05 Teva Pharma Tratamiento de formas progresivas de esclerosis multiple con laquinimod.
KR20150143499A (ko) 2013-03-14 2015-12-23 테바 파마슈티컬 인더스트리즈 리미티드 라퀴니모드 나트륨의 결정 및 이의 개선된 제조방법
AU2015253330A1 (en) 2014-04-29 2016-12-01 Teva Pharmaceutical Industries Ltd. Laquinimod for the treatment of relapsing-remitting multiple sclerosis (RRMS) patients with a high disability status
US9956212B2 (en) 2014-09-23 2018-05-01 Active Biotech Ab Quinoline carboxamides for use in the treatment of multiple myeloma
KR102525805B1 (ko) 2014-11-19 2023-04-25 액티브 바이오테크 에이비 백혈병 치료용 퀴놀린 카르복사미드
DK3886858T3 (da) 2019-12-19 2022-08-22 Active Biotech Ab Forbindelser til behandling af øjensygdomme forbundet med for megen vaskularisering
WO2021175924A1 (en) 2020-03-03 2021-09-10 Active Biotech Ab Tasquinimod or a pharmaceutically acceptable salt thereof for use in combination therapy
KR20230043916A (ko) 2020-07-23 2023-03-31 에라스무스 유니버시티 메디컬 센터 로테르담 골수증식성 신생물의 새로운 치료학적 표적으로서 s100 단백질
AU2022208424A1 (en) 2021-01-18 2023-08-24 Active Biotech Ab Tasquinimod or a pharmaceutically acceptable salt thereof for use in the treatment of myelodysplastic syndrome
KR20240012436A (ko) 2021-05-25 2024-01-29 액티브 바이오테크 에이비 복수의 타스퀴니모드 입자 및 그 용도
WO2023275248A1 (en) 2021-07-02 2023-01-05 Active Biotech Ab A pharmaceutical product containing tasquinimod and a method for assessing the purity of said product

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE52670B1 (en) * 1981-03-03 1988-01-20 Leo Ab Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation
GB9108547D0 (en) * 1991-04-22 1991-06-05 Fujisawa Pharmaceutical Co Quinoline derivatives

Also Published As

Publication number Publication date
SE9801474D0 (sv) 1998-04-27
EP1073639B1 (en) 2002-11-27
DK1073639T3 (da) 2003-03-24
BR9909925B1 (pt) 2010-09-21
HUP0102084A2 (hu) 2001-11-28
CZ297439B6 (cs) 2006-12-13
ES2188242T3 (es) 2003-06-16
IS5615A (is) 2000-08-31
CA2329788C (en) 2004-11-23
ME00870B (me) 2008-11-28
CN1298393A (zh) 2001-06-06
IS2082B (is) 2006-02-15
ATE228505T1 (de) 2002-12-15
EP1073639A1 (en) 2001-02-07
HRP20000726B1 (en) 2009-04-30
PT1073639E (pt) 2003-04-30
DE69904162T2 (de) 2003-08-21
HUP0102084A3 (en) 2002-12-28
NO315606B1 (no) 2003-09-29
CN1113057C (zh) 2003-07-02
NO20005254D0 (no) 2000-10-19
IL138160A0 (en) 2001-10-31
BR9909925A (pt) 2001-01-09
AP2000001933A0 (en) 2000-12-31
NO20005254L (no) 2000-12-27
JP2002513006A (ja) 2002-05-08
EE200000613A (et) 2002-04-15
RU2197481C2 (ru) 2003-01-27
AU4301399A (en) 1999-11-16
JP4045069B2 (ja) 2008-02-13
CA2329788A1 (en) 1999-11-04
IL138160A (en) 2006-04-10
AP1293A (en) 2004-08-30
EE04275B1 (et) 2004-04-15
UA60354C2 (uk) 2003-10-15
HK1036618A1 (en) 2002-01-11
WO1999055678A1 (en) 1999-11-04
ZA200004601B (en) 2002-02-27
NZ506641A (en) 2002-03-28
CZ20003849A3 (cs) 2001-03-14
DE69904162D1 (de) 2003-01-09
AU747550B2 (en) 2002-05-16
PL190441B1 (pl) 2005-12-30
RS50029B (sr) 2008-11-28
TR200003061T2 (tr) 2001-01-22
PL343420A1 (en) 2001-08-13
ID26277A (id) 2000-12-14
HU227709B1 (en) 2011-12-28
KR100571534B1 (ko) 2006-04-14
HRP20000726A2 (en) 2001-04-30
YU61200A (sh) 2003-07-07

Similar Documents

Publication Publication Date Title
EP1073639B1 (en) Quinoline derivatives
US6077851A (en) Quinoline derivatives
EP1095021B1 (en) Quinoline derivatives
US6133285A (en) Quinoline derivatives
US6121287A (en) Quinoline derivatives
EP1097139B1 (en) Quinoline derivatives
MXPA00009954A (en) Quinoline derivatives
MXPA01000388A (en) Quinoline derivatives
KR20010043066A (ko) 퀴놀린 유도체